SCHEMBL2885055

SCHEMBL2885055

OB(O)Oc1ccccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TSHR P16473 1/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
PKM P14618 1/20 0.39
CXCL8 P10145 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.37
HTT P42858 3/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
TP53 P04637 1/20 0.37
ENPP2 Q13822 1/20 0.37
SLC6A4 P31645 3/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A3 Q01959 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
USP2 O75604 1/20 0.36
PTK2B Q14289 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium SCHEMBL8009526 0.98 LMNA (0.41) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL30241159 0.83 CYP2A6 (0.40) LMNASMN1; SMN2TSHRKMT2AALDH1A1
SCHEMBL29544564 0.82 TSHR (0.43) SMN1; SMN2TSHRMEN1KMT2AALDH1A1
SCHEMBL6680350 0.82 TSHR (0.43) SMN1; SMN2TSHRMEN1KMT2AALDH1A1
SCHEMBL29706601 0.82 ENPP2 (0.44) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL6678412 0.82 ENPP2 (0.44) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL17602712 0.80 TSHR (0.37) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL738763 0.80 TSHR (0.45) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL30984399 0.79 CYP1A2 (0.52) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL27570492 0.79 ENPP2 (0.41) LMNASMN1; SMN2TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745280-B1 POTENTIOMETRIC ELECTRODE WITH A GRADIENT POLYMER COMPRISING CONDUCTIVE PARTICLES AND IONOPHORE MOLECULES, ITS MANUFACTURE AND USE PION INC (US) 2022-09-07 EP claimed
US-7857962-B2 Potentiometric electrode, gradient polymer, uses and method of preparation therefor UNIVERSITEIT ANTWERPEN (BE) 2010-12-28 US claimed
EP-1745280-A2 POTENTIOMETRIC ELECTRODE WITH A GRADIENT POLYMER COMPRISING CONDUCTIVE PARTICLES AND IONOPHORE MOLECULES AIC (BE) 2007-01-24 EP claimed
WO-2005103664-A2 POTENTIOMETRIC ELECTRODE WITH A GRADIENT POLYMER COMPRISING CONDUCTIVE PARTICLES AND IONOPHORE MOLECULES AIC (BE) 2005-11-03 WO claimed
CN-122094955-A Compound, light-emitting device, display device, electronic apparatus, and lighting device 2026-05-26 CN disclosed
CN-122036692-A Quinazoline compound, precursor, derivative and application thereof 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 2026-05-15 CN disclosed
CN-120202207-A Compound for organic electric element, organic electric element using the same, and electronic device using the same 德山新勒克斯有限公司 2025-06-24 CN disclosed
CN-119331001-B Efficient narrow-band luminescent material embedded with dibenzothiophene, and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2025-06-10 CN disclosed
CN-114072393-B 3-Amino-4H-benzo [ E ] [1,2,4] thiadiazine 1, 1-dioxide derivatives as MRGX2 inhibitors 索伦特治疗有限责任公司 2025-05-27 CN disclosed
CN-120005686-A Composition comprising lipase and sulfite 诺维信公司 2025-05-16 CN disclosed
CN-116332914-B Compound for organic electric element, organic electric element using the same, and electronic device using the same 德山新勒克斯有限公司 2025-04-15 CN disclosed
CN-115023414-B Compound for organic electronic element, organic electronic element using the same, and electronic device using the same 德山新勒克斯有限公司 2025-03-28 CN disclosed
EP-0675118-B1 Biphenylderivatives, process for their preparation and their use as medicaments EISAI CO LTD (JP) 2002-10-09 EP disclosed
US-6455720-B1 AS CATALYSTS TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-09-24 US disclosed
US-20020058837-A1 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-05-16 US disclosed
EP-1167372-A1 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst Takasago International Corporation (JP) 2002-01-02 EP disclosed
EP-1137641-A1 PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2001-10-04 EP disclosed
US-6281214-B1 USEFUL FOR TREATING AND AMELIORATING MENTAL DISORDERS EISAI CO., LTD (JP) 2001-08-28 US disclosed
WO-2000034249-A1 PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-06-15 WO disclosed
EP-0675118-A2 Biphenylderivatives, process for their preparation and their use as medicaments Eisai Co., Ltd. (JP) 1995-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058837-A1 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst DDT, PDCD11, PLD2 LMNA 4620/4885SMN1; SMN2 4274/4885TSHR 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.